Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew W Roberts

Showing results (151-160 of 198) with videos related to

Pageof 20
Sort By:
Blood|July 26, 2019
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLLConstantine S Tam, Judith Trotman, Stephen Opat, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 9, 2010
Deficiency of 5-hydroxyisourate hydrolase causes hepatomegaly and hepatocellular carcinoma in miceWilliam S Stevenson, Craig D Hyland, Jian-Guo Zhang, et al.
Blood|June 16, 2011
Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of plateletsSimone M Schoenwaelder, Kate E Jarman, Elizabeth E Gardiner, et al.
The Journal of Experimental Medicine|May 27, 2015
Aberrant actin depolymerization triggers the pyrin inflammasome and autoinflammatory disease that is dependent on IL-18, not IL-1βMan Lyang Kim, Jae Jin Chae, Yong Hwan Park, et al.
Blood|April 13, 2016
The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanismMary Ann Anderson, Jing Deng, John F Seymour, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 20, 2011
Fas-mediated neutrophil apoptosis is accelerated by Bid, Bak, and Bax and inhibited by Bcl-2 and Mcl-1Ben A Croker, Joanne A O'Donnell, Cameron J Nowell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2011
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory diseaseAndrew W Roberts, John F Seymour, Jennifer R Brown, et al.
Internal Medicine Journal|August 8, 2017
Bisphosphonate guidelines for treatment and prevention of myeloma bone diseaseOi Lin Lee, Noemi Horvath, Cindy Lee, et al.
Blood|August 30, 2017
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MMPhilippe Moreau, Asher Chanan-Khan, Andrew W Roberts, et al.
The Journal of Experimental Medicine|September 14, 2011
Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce plateletsEmma C Josefsson, Chloé James, Katya J Henley, et al.
Pageof 20

Showing results (151-160 of 198) with videos related to

Sort By:
Pageof 20
Blood|July 26, 2019
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLLConstantine S Tam, Judith Trotman, Stephen Opat, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 9, 2010
Deficiency of 5-hydroxyisourate hydrolase causes hepatomegaly and hepatocellular carcinoma in miceWilliam S Stevenson, Craig D Hyland, Jian-Guo Zhang, et al.
Blood|June 16, 2011
Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of plateletsSimone M Schoenwaelder, Kate E Jarman, Elizabeth E Gardiner, et al.
The Journal of Experimental Medicine|May 27, 2015
Aberrant actin depolymerization triggers the pyrin inflammasome and autoinflammatory disease that is dependent on IL-18, not IL-1βMan Lyang Kim, Jae Jin Chae, Yong Hwan Park, et al.
Blood|April 13, 2016
The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanismMary Ann Anderson, Jing Deng, John F Seymour, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 20, 2011
Fas-mediated neutrophil apoptosis is accelerated by Bid, Bak, and Bax and inhibited by Bcl-2 and Mcl-1Ben A Croker, Joanne A O'Donnell, Cameron J Nowell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2011
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory diseaseAndrew W Roberts, John F Seymour, Jennifer R Brown, et al.
Internal Medicine Journal|August 8, 2017
Bisphosphonate guidelines for treatment and prevention of myeloma bone diseaseOi Lin Lee, Noemi Horvath, Cindy Lee, et al.
Blood|August 30, 2017
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MMPhilippe Moreau, Asher Chanan-Khan, Andrew W Roberts, et al.
The Journal of Experimental Medicine|September 14, 2011
Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce plateletsEmma C Josefsson, Chloé James, Katya J Henley, et al.
Pageof 20